Personalized vaccine takes on pancreatic cancer in early trial

NCT ID NCT04627246

Ongoing Disease control Sponsor: Centre Hospitalier Universitaire Vaudois Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a personalized vaccine made from a patient's own immune cells, combined with standard chemotherapy and an immunotherapy drug (nivolumab), for people whose pancreatic cancer was removed by surgery. The goal is to see if the vaccine can be made successfully and is safe. Only 14 participants are enrolled, so results are very preliminary.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: personalized dendritic cell vaccine (PEP-DC) plus chemotherapy (mFOLFIRINOX or gemcitabine/capecitabine) plus nivolumab
What this could lead to: If this works, it could point toward a new way to prevent pancreatic cancer from coming back after surgery.
What could go wrong: This is a very early phase 1 trial with only 14 people, so it is mainly checking safety and feasibility. The vaccine is personalized, which makes it complex and hard to scale. There is no guarantee it will improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma neoplasm pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC ADENOCARCINOMA

Contacts and locations

Locations

CHUV Oncology Department

Lausanne, Canton of Vaud, 1011, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.